Revelation Biosciences closed at $4.12 on Nov 4, down 7.05%, 87.7% below its 52-week closing high. Volume of 11.4K shares was 0.18× its 20-day average (below normal).
Split-adjusted performance: -21.8% over one month, -42.3% over six months, -87.7% over one year.
Short interest was 6.6K shares at the Oct 15 settlement, up 317.8% from the prior report (0.2% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| REVBRevelation Biosciences | $4.12 | −7.05% | −42.3% | — | — | — | $2.3M | |
| ERNAErnexa Therapeutics | $1.99 | −1.49% | −67.1% | — | — | — | $2.3M | Compare |
| HCWBHCW Biologics | $1.08 | −6.09% | −48.6% | +1969.7% | −11340.3% | — | $2.4M | Compare |
| APVOAptevo Therapeutics | $1.37 | +0.74% | −72.3% | — | — | — | $2.5M | Compare |
| SBFMSunshine Biopharma | $2.65 | −3.28% | −98.8% | −1.6% | −16.9% | — | $2.0M | Compare |
| SILOSilo Pharma | $1.33 | +3.91% | −78.9% | −100.0% | — | — | $2.9M | Compare |
| PPCBPropanc Biopharma | $1.79 | +4.68% | −92.9% | — | — | — | $1.8M | Compare |
| GRIGRI Bio | $1.43 | −7.14% | −39.4% | — | — | — | $3.1M | Compare |
| GNPXGenprex | $2.14 | −7.36% | −89.1% | — | — | — | $1.8M | Compare |
No recent articles focused on Revelation Biosciences.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
